Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
- Conditions
- Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
- Interventions
- Drug: BortezomibDrug: Daratumumab and Hyaluronidase-fihjDrug: DexamethasoneDrug: Panobinostat Lactate
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Abdullah Khan
- Target Recruit Count
- 1
- Registration Number
- NCT04956302
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
The Effect of Dilution and Prolonged Injection Time on Dexamethasone-induced Perineal Irritation
- Conditions
- Adverse Effect
- Interventions
- Other: Diluted dexamethasone 20mlOther: Diluted dexamethasone 10mlOther: Diluted dexamethasone 5mlDrug: Dexamethasone
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- General Hospital of Ningxia Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT04950049
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Juan Du
- Target Recruit Count
- 90
- Registration Number
- NCT04941937
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT04933539
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 18
- Registration Number
- NCT04925193
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT04923893
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
- Conditions
- Extranodal NK/T-cell Lymphoma
- Interventions
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04917250
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, China
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
- Conditions
- Plasmablastic Lymphoma
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 28
- Registration Number
- NCT04915248
- Locations
- 🇮🇹
A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona, Ancona, Italy
🇮🇹Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati, Aviano, Italy
🇮🇹A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT04912427
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
The DEPOT Study (Dry Eye Prescription Options for Therapy)
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Research Insight LLC
- Target Recruit Count
- 50
- Registration Number
- NCT04911361
- Locations
- 🇺🇸
Inland Eye Specialists, Hemet, California, United States
🇺🇸Harvard Eye Associates, Laguna Hills, California, United States
🇺🇸Ophthalmology Associates, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.